CPT only copyright 2011 American Medical Association. Page 2 of 5 What You Need to Know This article explains the difference between a National Provider Identifier (NPI) and a Provider Transaction Access Number (PTAN). There are no policy changes in this article.
For people with aggressive B cell non-Hodgkin lymphoma, we commonly recommend a chemotherapy treatment called R-CHOP. It is named after the medicines included in the mixture: rituximab (RituxanÂ®), a monoclonal antibody that helps your immune system destroy the cancer cells and makes the chemotherapy more powerful
The two main types of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma. The differences in these two types of lymphoma are certain unique characteristics of the different lymphoma cells. Non-Hodgkin lymphoma is further classified into a variety of subtypes based on the cell of origin (B-cell or T-cell), and the cell characteristics. The subtype of Non-Hodgkin lymphoma predicts the necessity of early treatment, the response to treatment, the type of treatment required, and the prognosis. Non-Hodgkin lymphoma is much more common than Hodgkin lymphoma. Non-Hodgkin lymphoma is the seventh most common cause of cancer-related deaths in the United States. The risk of developing non-Hodgkin lymphoma increases with age and it is more common in males than in females and in Caucasians.